What does CUSIP 35104E100 represent in this 13F holders report?

CUSIP 35104E100 is the security identifier for FDMT - 4D Molecular Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held FDMT - 4D Molecular Therapeutics, Inc. - Common Stock in Q1 2021?

63 institutional investors reported FDMT - 4D Molecular Therapeutics, Inc. - Common Stock for Q1 2021. Use the holders table for investor-level position and value details.

4D Molecular Therapeutics, Inc. - Common Stock (FDMT)

CUSIP: 35104E100

Q1 2021 13F Holders as of 31 Mar 2021

Type / Class: Equity / Common Stock
Shares outstanding: 50,943,214
Total 13F shares: 15,384,514
Share change: +775,033
Total reported value: $664,816,567
Price per share: $43.38
Number of holders: 63
Value change: +$34,097,345
Number of buys: 38
Number of sells: 29

Quarterly Holders Quick Answers

What is CUSIP 35104E100?
CUSIP 35104E100 identifies FDMT - 4D Molecular Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2021
Previous quarter: Q4 2020

Recent filing periods for CUSIP 35104E100:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of FDMT - 4D Molecular Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
VIKING GLOBAL INVESTORS LP	13F	Company	7.7%	3,937,914	$163,227,000	—	31 Dec 2020	13F
FMR LLC	13F	Company	3.1%	1,594,355	$66,086,000	—	31 Dec 2020	13F
BVF INC/IL	13F	Company	2.2%	1,106,070	$45,847,000	—	31 Dec 2020	13F
ArrowMark Colorado Holdings LLC	13F	Company	2.1%	1,063,744	$44,092,000	—	31 Dec 2020	13F
JANUS HENDERSON GROUP PLC	13F	Company	2%	1,021,911	$39,907,000	—	31 Dec 2020	13F
Casdin Capital, LLC	13F	Company	1.5%	780,555	$32,354,000	—	31 Dec 2020	13F
SB Management Ltd	13F	Company	1.4%	717,734	$29,750,000	—	31 Dec 2020	13F
PERCEPTIVE ADVISORS LLC	13F	Company	1.2%	600,256	$24,881,000	—	31 Dec 2020	13F
ALKEON CAPITAL MANAGEMENT LLC	13F	Company	0.79%	401,885	$16,658,000	—	31 Dec 2020	13F
Octagon Capital Advisors LP	13F	Company	0.74%	377,777	$15,659,000	—	31 Dec 2020	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.68%	344,283	$14,271,000	—	31 Dec 2020	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.67%	343,678	$14,245,000	—	31 Dec 2020	13F
MORGAN STANLEY	13F	Company	0.48%	245,705	$10,184,000	—	31 Dec 2020	13F
HHLR ADVISORS, LTD.	13F	Company	0.44%	225,000	$9,326,000	—	31 Dec 2020	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.41%	209,179	$8,670,000	—	31 Dec 2020	13F
Cormorant Asset Management, LP	13F	Company	0.39%	200,000	$8,290,000	—	31 Dec 2020	13F
Ally Bridge Group (NY) LLC	13F	Company	0.29%	150,000	$6,218,000	—	31 Dec 2020	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	0.29%	150,000	$6,218,000	—	31 Dec 2020	13F
FEDERATED HERMES, INC.	13F	Company	0.29%	150,000	$6,218,000	—	31 Dec 2020	13F
ORBIMED ADVISORS LLC	13F	Company	0.25%	125,000	$5,181,000	—	31 Dec 2020	13F
Woodline Partners LP	13F	Company	0.2%	103,453	$4,288,000	—	31 Dec 2020	13F
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	0.2%	100,000	$4,145,000	—	31 Dec 2020	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.15%	74,978	$3,108,000	—	31 Dec 2020	13F
Laurion Capital Management LP	13F	Company	0.11%	58,000	$2,404,000	—	31 Dec 2020	13F
CITADEL ADVISORS LLC	13F	Company	0.1%	52,463	$2,175,000	—	31 Dec 2020	13F
Eagle Health Investments LP	13F	Company	0.1%	50,000	$2,073,000	—	31 Dec 2020	13F
J. Goldman & Co LP	13F	Company	0.09%	48,287	$2,001,000	—	31 Dec 2020	13F
Marshall Wace North America L.P.	13F	Company	0.07%	35,825	$1,485,000	—	31 Dec 2020	13F
PARAMETRIC PORTFOLIO ASSOCIATES LLC	13F	Company	0.07%	34,444	$1,428,000	—	31 Dec 2020	13F
SG Americas Securities, LLC	13F	Company	0.07%	33,680	$1,396,000	—	31 Dec 2020	13F
ExodusPoint Capital Management, LP	13F	Company	0.07%	33,152	$1,374,000	—	31 Dec 2020	13F
TD ASSET MANAGEMENT INC	13F	Company	0.05%	27,448	$1,138,000	—	31 Dec 2020	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.04%	20,000	$829,000	—	31 Dec 2020	13F
Aquilo Capital Management, LLC	13F	Company	0.04%	20,000	$829,000	—	31 Dec 2020	13F
Pinz Capital Management, LP	13F	Company	0.04%	19,900	$825,000	—	31 Dec 2020	13F
Qube Research & Technologies Ltd	13F	Company	0.03%	16,496	$684,000	—	31 Dec 2020	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.03%	12,780	$529,000	—	31 Dec 2020	13F
Mirae Asset Global Investments Co., Ltd.	13F	Company	0.02%	12,000	$498,000	—	31 Dec 2020	13F
M&T BANK CORP	13F	Company	0.02%	10,495	$435,000	—	31 Dec 2020	13F
Monashee Investment Management LLC	13F	Company	0.02%	10,000	$415,000	—	31 Dec 2020	13F
VICTORY CAPITAL MANAGEMENT INC	13F	Company	0.02%	10,000	$415,000	—	31 Dec 2020	13F
VANGUARD GROUP INC	13F	Company	0.02%	10,000	$414,000	—	31 Dec 2020	13F
MIRABELLA FINANCIAL SERVICES LLP	13F	Company	0.02%	8,330	$345,000	—	31 Dec 2020	13F
Engineers Gate Manager LP	13F	Company	0.02%	8,139	$337,000	—	31 Dec 2020	13F
MARSHALL WACE, LLP	13F	Company	0.01%	7,436	$308,000	—	31 Dec 2020	13F
Maven Securities LTD	13F	Company	0.01%	6,500	$271,000	—	31 Dec 2020	13F
BlackRock Finance, Inc.	13F	Company	0.01%	5,928	$246,000	—	31 Dec 2020	13F
SECTORAL ASSET MANAGEMENT INC	13F	Company	0.01%	5,224	$217,000	—	31 Dec 2020	13F
CAAS CAPITAL MANAGEMENT LP	13F	Company	0.01%	5,000	$207,000	—	31 Dec 2020	13F
NORGES BANK	13F	Company	0.01%	5,000	$207,000	—	31 Dec 2020	13F

Institutional Holders of 4D Molecular Therapeutics, Inc. - Common Stock (FDMT) as of Q1 2021

As of 31 Mar 2021, 4D Molecular Therapeutics, Inc. - Common Stock (FDMT) was held by 63 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 15,384,514 shares. The largest 10 holders included VIKING GLOBAL INVESTORS LP, FMR LLC, JANUS HENDERSON GROUP PLC, ArrowMark Colorado Holdings LLC, BVF INC/IL, Casdin Capital, LLC, BlackRock Inc., PERCEPTIVE ADVISORS LLC, VANGUARD GROUP INC, and ALKEON CAPITAL MANAGEMENT LLC. This page lists 63 institutional shareholders reporting positions in this security for the Q1 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2021 vs Q4 2020 Across Filers

Q4 2020 holders

Q1 2021 holders

Holder diff

Investor	Q4 2020 Shares	Q1 2021 Shares	Share Diff	Share Chg %	Q4 2020 Value $	Q1 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.